Allianz Research Institute Inc — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$152,041	51
2024	Research	$112,973	51
2023	Research	$198,958	52
2022	Research	$103,944	23
2021	Research	$392,296	6
2020	Research	$28,101	2
2019	Research	$306,939	27

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $379,446 4 payments
Sanofi US Services Inc. $339,909 54 payments
GlaxoSmithKline, LLC. $171,891 6 payments
Chiesi USA, Inc. $167,434 42 payments
Genzyme Corporation $139,260 42 payments
Sanofi-Aventis U.S. LLC $43,567 4 payments
Regeneron Pharmaceuticals, Inc. $42,135 55 payments
Novo Nordisk AS $11,612 5 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $357,656 2 payments
A Phase IV, 12 Week, Randomised, Double Blind Study to Compare Single $161,441 5 payments
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma $128,160 41 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $81,211 19 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma $72,778 8 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of SAR440340, in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $66,720 8 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis $54,700 11 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $53,634 13 payments
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $43,768 10 payments
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers $41,780 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.